Tonghua Dongbao Pharmaceutical (600867.SH) announced that in May 2024, the company signed a Commercial Authorization and MAH Cooperation Agreement on GLP-1 product semaglutide injection with Beijing Peptide Biopharmaceutical Technology Co., Ltd. (referred to as "Peptide Biopharm"). According to the agreement, the company will obtain the exclusive commercialization rights of Peptide Biopharm's clinical research product ZT001 semaglutide injection (indication: adult type 2 diabetes, currently using the name THDB0225 injection) in mainland China, as well as the right to jointly develop overseas markets. The collaborative product has completed Phase I clinical trials in mainland China, and Tonghua Dongbao has initiated Phase III clinical trials in China and has successfully completed the first patient dosing recently.
The Zhitong Finance APP announced that Tonghua Dongbao (600867.SH) signed a Commercial Authorization and MAH Cooperation Agreement with Beijing Peptide Biopharmaceutical Technology Co., Ltd. (referred to as "Peptide Biopharm") in May 2024 regarding the GLP-1 product semaglutide injection. According to the agreement, the company will obtain the exclusive commercialization rights of Peptide Biopharm's clinical research product ZT001 semaglutide injection (indication: adult type 2 diabetes, currently using the name THDB0225 injection) in mainland China, as well as the right to jointly develop overseas markets. The collaborative product has completed Phase I clinical trials in mainland China, and Tonghua Dongbao has initiated Phase III clinical trials in China and has successfully completed the first patient dosing recently.